A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

(2014) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

(2014) Yingmiao Liu et al.   INVESTIGATIONAL NEW DRUGS

Systemic therapy in HCC: Lessons from brivanib

(2014) David Bolos et al.   JOURNAL OF HEPATOLOGY

Endoglin for Targeted Cancer Treatment

(2014) Lee S. Rosen et al.   Current Oncology Reports

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

(2014) Yingmiao Liu et al.   Cancer Medicine

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

(2013) A. B. Nixon et al.   CLINICAL CANCER RESEARCH

New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma

(2013) R. Lencioni   CLINICAL CANCER RESEARCH

Everolimus is a potent inhibitor of activated hepatic stellate cell functionsin vitroandin vivo, while demonstrating anti-angiogenic activities

(2013) Anne-Christine Piguet et al.   CLINICAL SCIENCE

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

(2013) Josep M. Llovet et al.   JOURNAL OF CLINICAL ONCOLOGY

Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database

(2013) Tobias Eggert et al.   United European Gastroenterology Journal

Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies

(2012) Austin Duffy et al.   HEPATOLOGY

Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies

(2012) Olivier Nolan-Stevaux et al.   PLoS One

Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives

(2012) Andrew X. Zhu   SEMINARS IN ONCOLOGY

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

(2010) Fumihiko Kanai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Matrix Metalloproteinase-14 (MT1-MMP)-Mediated Endoglin Shedding Inhibits Tumor Angiogenesis

(2010) L. J. A. C. Hawinkels et al.   CANCER RESEARCH

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

(2010) D. Koeberle et al.   ONCOLOGIST

Developing better treatments in hepatocellular carcinoma

(2010) Austin Duffy et al.   Expert Review of Gastroenterology & Hepatology

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

(2009) A. Rapisarda et al.   MOLECULAR CANCER THERAPEUTICS

Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy

(2008) N. A. Dallas et al.   CLINICAL CANCER RESEARCH

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE